Physician profile
Duc Nguyen
NPI 1306945365
$20,184.89
in general payments reported to CMS, 2019-2025
47 companies · $2,937 in 2025
The $2,937 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,935 · 2020: $2,163 · 2021: $2,520 · 2022: $2,049 · 2023: $2,813 · 2024: $4,767 · 2025: $2,937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,285 · Consulting Fee: $2,100 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,284.99 |
| Consulting Fee | $2,100.00 |
| Education | $132.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $4,277.95 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Astrazeneca Pharmaceuticals LP | $3,371.15 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $2,971.83 | 2019-2025 | Nucala, Arexvy |
| Amgen INC. | $1,885.26 | 2019-2025 | Tezspire, Otezla, Repatha |
| Regeneron Healthcare Solutions, INC. | $631.75 | 2019-2025 | Dupixent |
| Abbvie INC. | $629.87 | 2021-2025 | |
| Genzyme Corporation | $549.33 | 2019-2025 | |
| Radius Health, INC. | $546.43 | 2019-2023 | Tymlos |
| Allergan, INC. | $539.55 | 2019-2020 | |
| Mylan Specialty L.P. | $525.18 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $415.06 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $406.40 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $365.82 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $282.98 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $263.03 | 2019-2025 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duc Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.